DERM on RheumNow (April 2026)

DERM on RheumNow (April 2026)

From Rheumnow Podcast by Dr. Cush

May 1, 2026 · 16 min · Episode 1483

About this episode

This episode covers various dermatological topics including psoriasis, PsA, and the efficacy of dermatology drugs.

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: Chinese target emulation trial of MDA-5+, dermatomyositis w/ ILD. 106 Rx w/ UPA & 328 w/ TOFA. 6-month lung transplantation-free survival 72% vs 67% (UPA v TOFA). UPA non-inferior to TOFA in MDA5+DM-ILD https://t.co/BBAfbM06AM In 2025 DTC TV ad spending by top 10 incr to $2.67 billion (up from $2.1 B). Rheum Drugs in top 3: 1. Skyrizi $440 million 2. Tremfya $431 M 3. Rinvoq $376 M https://t.co/EsWgUqUy9Z 2. Dermatology Salaries 2025 – Dermatology is top 10 at $448K according to Medscape; expected to go down -1% in 2026; derms made up 2% of survey group 37K MDs 3. Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mean age 55 yrs; 40% w/ diffuse SSc. Itch (moderate 4/10) seen in ~35% at all times https://t.co/QnT8d0xA5Z 4. Asia-Pacific Lupus study of Mucocutaneous activity (MC-A) in 4102 SLE pts. 36% had…

People in this episode

Host: Dr. Jack Cush

Topics covered

  • dermatology
  • psoriasis
  • PsA
  • vasculitis
  • CTD skin disorders
  • biologics
  • JAKs

Keywords

  • dermatology
  • Psoriasis
  • PsA
  • biologics
  • JAKs
  • scleroderma
  • calcinosis cutis
  • mucocutaneous activity

Mentioned in this episode

Organizations: RheumNow.com

Products: Skyrizi, Tremfya, Rinvoq

Places: Asia-Pacific

More episodes of Rheumnow Podcast

Explore listener stats, chart rankings, contacts and more on the Rheumnow Podcast podcast page.